ZHOU LABORATORY 
Protein Drug Design and Molecular Diagnostics

中文版本
The research group of Dr. Zigang Li/Dr. Feng Yin of Pingshan Center and the research group of Dr. Yaoqi Zhou of Shenzhen Bay Laboratory have made research progress in the development of anti-COVID-19 polypeptide drug conjugates (PDCs).
Posted onJan 05,2022

Recently, Dr. Zigang Li/Dr. Feng Yin's research group from Pingshan Center cooperated with Dr. Yaoqi Zhou's research group from Shenzhen Bay Laboratory to develop a novel polypeptide-drug conjugate targeting the papain-like protease (PLpro) protein of the new coronavirus (SARS-CoV-2). The results were published in the Journal of Medicinal Chemistry with the title of "Design and Evaluation of a Novel Peptide-Drug Conjugate Covalently Targeting SARS-CoV-2 Papain-Like Protease (PLpro)".

2022.1.5科研动态.jpg